Boston Scientific will pay $269m for the 84% of the thrombectomy technology developer that it does not currently own.

Medical equipment manufacturer Boston Scientific Corporation has agreed to acquire US-based thrombectomy platform developer Devoro Medical for $269m.

Devoro Medical’s WOLF platform removes blood clots like deep vein thrombosis, peripheral artery occlusions or pulmonary embolisms through prongs inserted into veins or arteries.

Boston Scientific already owns a 16% stake in Devoro stemming from a strategic investment in 2019, when Devoro Medical raised approximately $8.5m in August from 16 unnamed investors according to a regulatory filing.

The latest deal involves the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn